Gene may be key to response to ADHD drug

VANCOUVER, British Columbia, May 4 (UPI) -- U.S. researchers say gene research may help those taking drugs for attention-deficit hyperactivity disorder.

Researchers at Ohio's Cincinnati Children's Hospital Medical Center found those with a specific type of dopamine receptor gene responded better to the drug methylphenidate than those without the genotype.


"With more information about genes that may be involved in ADHD medication response, we might be able to predict treatment course, tailor our approach to each child, and improve symptom response while decreasing health care costs," Dr. Tanya Froehlich said in a statement.

The goal, Froehlich says, is to deliver the greatest symptom improvement with the fewest side effects.

Froehlich and colleagues conducted the placebo-controlled pharmacogenetic drug trial in school-age children and asked teachers to rate the children's symptoms.

The findings were presented at the annual meeting of the Pediatric Academic Societies in Vancouver.

Latest Headlines